Supplements With Evidence In Mild Cognitive Impairment
Quick Read Mild cognitive impairment is a grey zone between normal age-related memory changes and dementia, and it may be
Subscribe to the distribution list, to get regular updates on supplement research for health,
🧠 NeuroBright Our evidence-based brain supplement formulated from 1.7M research papers
People with ADHD consistently have lower omega-3 fatty acid levels in their blood than those without it, even when eating similar amounts of fish. Omega-3s, particularly two types called DHA and EPA, are physically woven into brain cell membranes and help regulate the chemical messengers involved in attention and impulse control. The brain region responsible for focus and executive function is especially rich in these fatty acids.
Some studies show that taking 2,000mg or more of omega-3 daily improves attention and memory, but the evidence quality is considered low to moderate. The benefits appear strongest in people who are genuinely deficient in omega-3 to begin with. A small trial in people with autism and ADHD showed meaningful improvements in attention after four weeks of fish oil. However, a major genetic study found no causal link between omega-3 levels and ADHD, suggesting low levels might be a result of the condition rather than a cause.
Most research has focused on children, and adult-specific evidence is limited. The optimal dose remains unclear, and most trials lasted only 12 to 26 weeks, so long-term effects are unknown. New research suggests combining omega-3 with another fatty acid called GLA may work better than omega-3 alone for attention problems.
Verdict: Omega-3 is a reasonable, low-risk addition for people with ADHD or those with low omega-3 intake, but it should complement other treatments rather than replace them, and benefits are most likely if you’re genuinely deficient.
Here’s a question worth sitting with: if your brain is genuinely short of a nutrient it needs to regulate attention, could the answer to your focus problems be swimming in the sea? Adults with ADHD, and the millions more who suspect they might have it but were never diagnosed, are increasingly turning to omega-3 fish oil supplements in search of a calmer, clearer mind. But the science here is genuinely complicated. Not in a hand-wavy, “more research needed” kind of way. Complicated in the sense that some studies show real, measurable improvements in attention and focus, others find almost nothing, and one major genetic analysis suggests omega-3 levels might not cause ADHD at all. So what’s actually going on? Vitacuity analysed over 1.77 million research papers and identified the 15 most relevant to this question. Here’s the honest, full picture.
To understand why omega-3 might matter for ADHD, you need to understand what it actually does in the brain, not in a vague, “good for brain health” way, but mechanistically.
The two key omega-3 fatty acids are DHA (docosahexaenoic acid) and EPA (eicosapentaenoic acid). DHA is a structural component of brain cell membranes, it’s physically woven into the fabric of your neurons, helping them stay fluid and responsive. EPA, by contrast, appears to be more involved in behaviour, mood and the signalling environment of the brain [5]. Together, they generate neuroprotective compounds and play a role in neurotransmitter regulation, including dopamine and norepinephrine, the systems most directly implicated in ADHD [2].
The prefrontal cortex, the region of the brain responsible for attention, impulse control, working memory and executive function, is particularly rich in DHA. It’s also the region most consistently implicated in ADHD [2]. So the theoretical link isn’t superficial. It’s grounded in real neurobiology.
Here’s the critical observation that has driven two decades of research: people with ADHD consistently show lower levels of omega-3 fatty acids in their blood compared to people without it. Multiple studies have found this, in both children and adults [9][10]. The question researchers have been wrestling with ever since is whether those lower levels are a *cause* of ADHD symptoms, a *consequence* of the condition (perhaps through altered metabolism), or simply a coincidence.
Evidence grade: Promising, consistent observational finding, causation unconfirmed
The pattern of lower omega-3 in people with ADHD has been replicated across multiple populations. A case-control study from Purdue University found that adults newly diagnosed with ADHD had significantly lower proportions of omega-3 fatty acids in both their plasma phospholipids and red blood cells compared to controls, despite having dietary omega intake that wasn’t significantly different from those without ADHD [9]. This is an important detail: it wasn’t simply that they were eating less fish. Something about how they metabolised or utilised omega-3 appeared to be different.
A separate Finnish study, Project DyAdd, compared fatty acid profiles in adults with ADHD, adults with dyslexia, those with both conditions, and healthy controls. Adults with ADHD had elevated levels of omega-6 PUFAs and a higher omega-6 to omega-3 ratio compared to those without ADHD [10]. In men specifically, ADHD was also associated with elevated nervonic acid, a pattern mirroring what was seen in dyslexia. The omega-6/omega-3 imbalance is significant because these two fatty acid families compete for the same metabolic pathways, too much omega-6 can actively crowd out omega-3 in the brain [10].
What this tells us: the omega-3 deficit in ADHD is a real, repeatedly observed biological phenomenon. But, and this matters, observational studies can’t tell us whether correcting it through supplementation will fix the problem.
Evidence grade: Promising, some meaningful human trial findings, but mixed overall
The largest and most recent synthesis comes from a 2025 systematic review and dose-response meta-analysis covering 58 randomised controlled trials in adults [1]. The headline finding: each additional 2,000 mg per day of omega-3 supplementation was associated with significant improvements in attention (standardised mean difference: 0.98), perceptual speed (SMD: 0.50), primary memory (SMD: 0.87), and global cognitive abilities (SMD: 1.08). These are not trivial effect sizes on paper.
However, and the researchers are admirably clear about this, the GRADE certainty of the evidence for attention and global cognition was rated *low*, and moderate for perceptual speed and memory. GRADE ratings reflect how confident we can be that the true effect matches what was found. Low certainty means the real-world effect could be considerably smaller, or even absent. There was also a non-linear relationship: global cognitive benefits appeared to increase with dose up to a point, then decline, suggesting more is not always better [1].
A smaller but more targeted piece of evidence comes from a crossover trial in 26 adults with autism spectrum disorder, many of whom had comorbid ADHD [8]. Participants received either fish oil (5.2g per day of omega-3) or a control oil for four weeks, then switched. In those with comorbid ADHD, fish oil improved ADHD symptom scores significantly (score change: -3.5 points vs -0.2 in those without ADHD). Working memory (Corsi block scores) improved by approximately 0.3 standard deviations across the group, and errors on an attention test were 30% lower after fish oil [8]. These are promising results, but 26 participants is a very small sample, and the four-week duration limits what conclusions we can draw.
Evidence grade: Promising, supported by specific RCT findings, dose matters
One of the more nuanced findings in this field is that EPA and DHA may have distinct roles, and EPA may be the dominant driver of cognitive and behavioural effects in ADHD [5].
A 12-week double-blind, placebo-controlled trial in 92 children and adolescents with ADHD compared high-dose EPA (1.2g per day) against placebo [12]. Overall, the EPA group improved more than placebo on focused attention (effect size: 0.38). But the really striking finding came from a subgroup analysis: in participants with the lowest baseline EPA levels, the EPA group showed dramatically larger improvements in focused attention (effect size: 0.89) and vigilance (effect size: 0.83) compared to placebo [12]. This is important context for adults who suspect they may be omega-3 deficient, the benefit appears strongest precisely in those who have the most ground to make up.
There was a counterintuitive finding too: those with *high* baseline EPA levels showed less improvement, and in some measures appeared to do worse on impulsivity scores. This suggests that omega-3 supplementation isn’t a blanket cognitive enhancer, it may work best as a correction for a specific deficiency [12].
Clinically, treatment guidelines for youth suggest a combined EPA + DHA dose of at least 750mg per day for ADHD, with higher EPA doses (around 1,200mg) recommended for those with markers of inflammation [11]. While these guidelines are aimed at children and adolescents, the underlying biological rationale is consistent with adult physiology.
Evidence grade: Early stage to Promising, mechanistic rationale plus early trial data
Here’s something that rarely gets discussed outside academic circles: omega-3 supplementation alone might not be sufficient for meaningful ADHD symptom improvement. A narrative review published in 2022 highlights the potential role of gamma-linolenic acid (GLA), an omega-6 fatty acid, as an adjuvant [14].
GLA’s anti-inflammatory properties work through a different pathway than EPA and DHA, it increases dihomo-gamma-linolenic acid in immune cells, which acts as a precursor to anti-inflammatory compounds. When combined with omega-3s, EPA and DHA appear to prevent the build-up of arachidonic acid (a pro-inflammatory omega-6) that GLA supplementation alone can sometimes cause [14].
A meta-regression analysis of 18 randomised controlled trials found that GLA content in a PUFA supplement, and particularly the interaction between GLA and EPA, was significantly associated with reductions in inattention scores, an effect that EPA or DHA alone did not consistently produce [15]. The overall pooled effect on combined ADHD symptoms across those 18 studies was statistically significant (SMD: -0.192), but modest. The researchers found that longer study duration and the GLA-EPA combination were the strongest predictors of benefit for inattention specifically [15].
The suggested ratio from the available evidence is EPA:DHA:GLA at approximately 9:3:1 [14]. This is speculative as a precise formula, but it points toward a more sophisticated supplementation approach than simply taking fish oil.
Evidence grade: Conflicted, results vary by baseline levels and age
Not everyone taking omega-3 for focus has an ADHD diagnosis. So what does the research say for generally healthy adults who simply want to maintain or sharpen their concentration?
A well-designed randomised controlled trial published in 2020 followed 271 mid-life adults (aged 30–54) with low habitual omega-3 intake. They received either 1,400mg per day of combined EPA and DHA, or placebo, for 18 weeks [6]. The result? No significant improvement in psychomotor speed, executive function, learning, episodic memory, or fluid intelligence across the group as a whole.
However, the exploratory finding is worth noting. In participants who started the trial with particularly low DHA levels, fish oil did improve executive function compared to placebo [6]. This echoes the EPA deficiency finding in the ADHD trials [12]: omega-3 supplementation may be most beneficial in those who are genuinely depleted, rather than those who are already sufficient.
On the memory side, a smaller placebo-controlled trial in 44 adults aged 50–75 found that 26 weeks of LC-omega-3 supplementation at 2,200mg per day significantly improved recall of object locations compared to placebo, a sensitive measure of spatial memory [7]. The omega-3 index (a blood marker of omega-3 status) increased significantly in the treatment group, and this correlated with memory improvements. Sample size was small (22 per group), but the design was rigorous.
The Cochrane Review finding for children and adolescents with ADHD is also honest to acknowledge: after reviewing the RCT evidence, the authors concluded there was “little evidence that PUFA supplementation improved symptoms of ADHD in children and adolescents” [3]. This doesn’t mean omega-3 definitively doesn’t work, but it does mean the evidence base is not nearly strong enough to present fish oil as an established ADHD treatment.
This is the section we never skip, because intellectual honesty is what distinguishes genuinely useful health information from marketing.
Causation remains unresolved. The Mendelian randomisation study, arguably the most rigorous type of observational evidence because it uses genetic variants as proxies for exposure, found no significant causal relationship between genetically predicted omega-3 levels and ADHD [4]. This is a serious challenge to the “low omega-3 causes ADHD” hypothesis. It suggests the low omega-3 observed in people with ADHD might be a downstream consequence of the condition rather than a root cause.
Adult-specific data is limited. The majority of ADHD and omega-3 research has been conducted in children and adolescents. The biological and neurological mechanisms are similar in adults, but not identical, ADHD presents differently in adults, executive function deficits become more prominent relative to hyperactivity, and hormonal environments differ. We cannot simply extrapolate from children’s trials to adult populations with confidence [2][3].
Optimal dosing is unclear. The 2025 meta-analysis found non-linear dose-response relationships, suggesting that more isn’t always better, and that there may be a sweet spot that varies by individual [1]. No long-term dose-ranging studies in adults with ADHD have established what this looks like in practice.
Baseline levels matter enormously, but aren’t routinely tested. The most consistent finding across multiple studies is that supplementation benefits those who are deficient most [6][12]. Yet omega-3 blood testing is not standard in ADHD assessments, leaving clinicians and individuals guessing.
The GLA story needs more research. The suggestion that EPA + GLA combinations outperform EPA alone for inattention is intriguing [14][15], but rests on meta-regression analysis and narrative review rather than head-to-head RCTs with this specific combination designed from the outset.
Long-term effects are unknown. Most trials run for 12–26 weeks. We don’t know whether sustained omega-3 supplementation over years has cumulative cognitive benefits, plateaus, or diminishing returns.
So, what would a sensible, well-informed person actually do with all of this?
First, let’s be clear about what the research doesn’t support: omega-3 is not a proven treatment for ADHD, and anyone framing it that way is overstating the evidence. The Cochrane review found little evidence for children, and adult data is sparser still [3]. If you’re managing ADHD, omega-3 should be considered a potential *complement* to other strategies, not a substitute for them.
What the research does support is more nuanced and genuinely interesting: omega-3 deficiency is common in people with ADHD, omega-3 plays a real role in brain cell structure and neurotransmitter function, and supplementation appears most beneficial in those who are genuinely deficient [5][9][12]. The dose-response meta-analysis showing attention improvements at 2,000mg per day is meaningful, even if the GRADE certainty is low [1].
Here’s how to think about this practically:
If you have ADHD (diagnosed or strongly suspected): Omega-3 is a genuinely reasonable addition to your routine. It’s safe, relatively inexpensive, and the biological rationale is sound. Aim for a combined EPA + DHA of at least 1,000–2,000mg per day, with EPA as the dominant form [11][12]. The emerging evidence suggests looking for a product that includes some GLA alongside the EPA and DHA [14][15]. Give it at least 12 weeks, short-term trials have often failed to capture effects that emerge with longer supplementation [15].
If you’re a healthy adult wanting to protect focus and cognition: The evidence is thinner here, but the risk of deficiency is real, particularly if you eat little to no oily fish. Omega-3 is a water-adjacent fat-soluble nutrient delivered via fish oil, but at normal supplement doses (1,000–3,000mg per day) it is safe and well-tolerated. The precautionary case for supplementing is reasonable. The mid-life trial showing executive function benefits specifically in those with low baseline DHA suggests that if you’re in the low-intake bracket, supplementation is sensible [6].
On testing: Omega-3 blood tests (the omega-3 index) do exist and can tell you your actual status, but they’re not widely available or cheap, and most people consuming typical Western diets with limited oily fish intake are likely to be running low anyway. A practical default is to supplement and eat oily fish two to three times a week if you can.
The one thing not to do: take a modest dose for two weeks, notice nothing dramatic, and give up. The research consistently shows that meaningful changes in brain omega-3 status take time, and the effects on subtle cognitive metrics like attention variability are not the kind of thing you’ll feel like a jolt of caffeine. This is biology working quietly, at a cellular level.
Omega-3 isn’t a miracle. But the evidence that your brain needs it, and that many of us aren’t getting enough, is solid enough to act on.
[1] A systematic review and dose response meta-analysis of omega-3 supplementation on cognitive function. (2025). DOI: 10.1038/s41598-025-16129-8 | https://pubmed.ncbi.nlm.nih.gov/40836005/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12368174/
[2] Omega-3 Polyunsaturated Fatty Acid Supplementation in Children With Attention-Deficit Hyperactivity Disorder (ADHD). (2025). DOI: 10.7759/cureus.93175 | https://pubmed.ncbi.nlm.nih.gov/41141173/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12553300/
[3] Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. (2023). https://pubmed.ncbi.nlm.nih.gov/37058600/
[4] Absence of Causal Relationship Between Levels of Unsaturated Fatty Acids and ADHD: Evidence From Mendelian Randomization Study. (2024). DOI: 10.1177/10870547241264660 | https://pubmed.ncbi.nlm.nih.gov/39082434/
[5] Omega-3 DHA and EPA for cognition, behavior, and mood: clinical findings and structural-functional synergies with cell membrane phospholipids. (2007). https://pubmed.ncbi.nlm.nih.gov/18072818/
[6] The effects of omega-3 fatty acids on neuropsychological functioning and brain morphology in mid-life adults: a randomized clinical trial. (2020). DOI: 10.1017/S0033291719002617 | https://pubmed.ncbi.nlm.nih.gov/31581959/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8109262/
[7] Impact of Omega-3 Fatty Acid Supplementation on Memory Functions in Healthy Older Adults. (2016). https://pubmed.ncbi.nlm.nih.gov/26890759/
[8] Fish oil supplementation may improve attention, working memory and attention-deficit/hyperactivity disorder symptoms in adults with autism spectrum disorder: a randomised crossover trial. (2022). DOI: 10.1017/S0007114522000393 | https://pubmed.ncbi.nlm.nih.gov/35144699/
[9] Omega-3 fatty acid status in attention-deficit/hyperactivity disorder. (2006). https://pubmed.ncbi.nlm.nih.gov/16962757/
[10] Project DyAdd: Fatty acids in adult dyslexia, ADHD, and their comorbid combination. (2009). https://pubmed.ncbi.nlm.nih.gov/19523794/
[11] Nutritional Neuroscience as Mainstream of Psychiatry: The Evidence-Based Treatment Guidelines for Using Omega-3 Fatty Acids as a New Treatment for Psychiatric Disorders in Children and Adolescents. (2020). DOI: 10.9758/cpn.2020.18.4.469 | https://pubmed.ncbi.nlm.nih.gov/33124582/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7609218/
[12] High-dose eicosapentaenoic acid (EPA) improves attention and vigilance in children and adolescents with attention deficit hyperactivity disorder (ADHD) and low endogenous EPA levels. (2019). DOI: 10.1038/s41398-019-0633-0 | https://pubmed.ncbi.nlm.nih.gov/31745072/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6864068/
[13] Efficacy of Omega-3 and Korean Red Ginseng in Children with Subthreshold ADHD: A Double-Blind, Randomized, Placebo-Controlled Trial. (2021). DOI: 10.1177/1087054720951868 | https://pubmed.ncbi.nlm.nih.gov/32847461/
[14] Relevance of ω-6 GLA Added to ω-3 PUFAs Supplements for ADHD: A Narrative Review. (2022). DOI: 10.3390/nu14163273 | https://pubmed.ncbi.nlm.nih.gov/36014778/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416383/
[15] Which polyunsaturated fatty acids are active in children with attention-deficit hyperactivity disorder receiving PUFA supplementation? A fatty acid validated meta-regression analysis of randomized controlled trials. (2014). https://pubmed.ncbi.nlm.nih.gov/24560325/
This article is for informational purposes only and does not constitute medical advice. Food supplements should not be used as a substitute for a varied and balanced diet and healthy lifestyle. If you are pregnant, breastfeeding, taking medication or have a medical condition, consult your doctor before taking any supplement. These statements have not been evaluated by the Food and Drug Administration (FDA) or the Medicines and Healthcare products Regulatory Agency (MHRA). This product is not intended to diagnose, treat, cure, or prevent any disease.
Quick Read Mild cognitive impairment is a grey zone between normal age-related memory changes and dementia, and it may be
Quick Read Your brain has a nightly cleaning system called the glymphatic system that removes toxic waste proteins during deep
